Introduction
Bell’s palsy is the commonest cause of acute VII-nerve weakness, with first-episode incidence typically 15 per 100,000 [1]. Although most attacks are self-limiting, 215% of patients experience further episodes [2]. This recurrence leads to delayed recovery and compounds functional and psychosocial disability. The clinical dilemma is stark: guidelines, evidence and even pathophysiological models have been constructed almost around first attacks, leaving clinicians to extrapolate when Bell’s recurs [2].
HSV-1 reactivation and the rationale for antiviral prophylaxis
A key area of controversy lies in the role of herpes simplex virus type 1 (HSV-1) in disease recurrence and use of prophylactic antivirals. Polymerase chain reaction studies have identified HSV-1 DNA in up to 79% of endoneurial fluid samples from patients with Bell’s palsy, implicating viral reactivation as a pathogenic mechanism [3]. However, no randomized controlled trial has evaluated efficacy of prophylactic antiviral therapy in patients with recurrent disease. Small series and case reports support valacyclovir use in individuals with frequent or disabling relapses, particularly those with confirmed HSV-1 DNA positivity, immunocompromised status, or a strong family history [2]. In the absence of robust trial data, a risk-stratified approach may be reasonable, offering antiviral prophylaxis to select patients while prospectively monitoring for recurrence frequency and treatment response.
Current gaps in guidelines and the need for standardized clinical frameworks
The absence of guidelines specific to recurrent Bell’s palsy hinders consistent care, as existing recommendations focus on first episodes and overlook recurrent nuances. Formal consensus guidelines are urgently needed, supported by prospective multicentre registries capturing standardized data—ranging from facial scores and imaging to immune markers and patient-reported outcomes—to refine diagnosis and inform future trials.
Randomized controlled trials are essential to determine whether antiviral prophylaxis alters the course of recurrent Bell’s palsy. Studies comparing long-term valacyclovir to placebo after a second episode—stratified by HSV DNA and immune profiles—should assess recurrence timing, House-Brackmann scores, and quality-of-life. Adaptive trial designs may clarify if combining corticosteroids with antivirals improves outcomes in severe or rapid-onset cases. Early adjunctive therapies like neuromuscular retraining also merit evaluation, given their efficacy in chronic facial paresis [4].
Emerging diagnostic and stratification tools
Neuroimaging and electrophysiological studies offer promising tools for both diagnosis and stratification. While contrast-enhanced 3T MRI is recommended to exclude mimics like demyelinating diseases, more advanced techniques—including high-resolution imaging and diffusion-based metrics—may enable detection of subtle nerve injury and inflammation [5]. Correlating these imaging features with clinical outcomes could guide decisions about decompression surgery or immunomodulatory therapies. Similarly, integration of viral serology and inflammatory cytokine profiling may facilitate identification of mechanistic biomarkers predictive of recurrence or treatment responsiveness.
Ultimately, recurrent Bell’s palsy should be recognized as a distinct clinical entity rather than a reiteration of first-episode disease. The prevailing reliance on empirical management reflects a missed opportunity to develop precision approaches rooted in virology, immunology, and neuroimaging. Advancing the field will require coordinated international collaboration to establish trial infrastructure, and therapeutic consensus—offering patients a pathway from uncertainty to evidence-based care.
Author contribution
All authors contributed to the conception, drafting, and critical revision of the manuscript and approved the final version. The authors thank colleagues and institutions who provided valuable input during the preparation of this work. No datasets were generated or analyzed in the current study, and thus availability of data and material is not applicable.
Funding
No funding was received for this work.
Declarations
Ethics approval
Ethics approval and consent to participate were not applicable.
Consent for publication
Consent for publication was not applicable.
Conflict of interest
The authors have no conflict of interest to declare.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Jeong J, Yoon SR, Lim H, Oh J, Choi HS. Risk factors for Bell’s palsy based on the Korean National Health Insurance Service National Sample Cohort data. Sci Rep. 2021/12/03 2021;11(1):23387. 10.1038/s41598-021-02816-9 [DOI] [PMC free article] [PubMed]
- 2.Mancini P, Bottaro V, Capitani F, et al. Recurrent Bell’s palsy: outcomes and correlation with clinical comorbidities. Acta Otorhinolaryngol Ital. 2019;39(5):316–21. 10.14639/0392-100x-2415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med. 1996;1(1 Pt 1):27–30. 10.7326/0003-4819-124-1_part_1-199601010-00005. [DOI] [PubMed] [Google Scholar]
- 4.Li Y, Li Z, Yan C, Hui L. The effect of total facial nerve decompression in preventing further recurrence of idiopathic recurrent facial palsy. Eur Arch Otorhinolaryngol. 2015/05/01 2015;272(5):1087–90. 10.1007/s00405-014-2891-z [DOI] [PubMed]
- 5.Ho M-L, Juliano A, Eisenberg RL, Moonis G. Anatomy and pathology of the facial nerve. Am J Roentgenol. 2015;06(6):W612–9. 10.2214/AJR.14.13444/012015 [DOI] [PubMed] [Google Scholar]